AUSTIN, Texas, Nov. 14 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. announced that during a conference bringing together representatives from pharmaceutical, biotechnology and government areas to showcase some of the industry’s most successful efforts in the viral application of therapeutics, two Introgen experts, Drs. Shuyuan Zhang and David L. Parker, will discuss the company’s expertise in the manufacture of adenoviral-based pharmaceuticals and its recommended guidelines for protecting intellectual property respectively. Both presentations will take place Wednesday, November 16.
Peter M. Clarke, Ph.D., Introgen’s vice president of Production and Technical Processes, said, “Introgen is a well recognized leader in the field of producing adenovirus based therapies. Additionally, with its in-house experience and portfolio of patents directed to highly purified adenoviral compositions, commercial scale production processes, and stable formulations, Introgen is well positioned to expeditiously develop further viral vectors and to rapidly commercialize its current product candidates upon regulatory approval.”
The Viral Vectors and Vaccines conference being held in Austin, is sponsored by the Williamsburg BioProcessing Foundation (Wilbio), founded to provide venues for the exchange of bioprocess technology. The conference will focus on the latest advances in production, purification and analytical methods as well as the trends in regulatory practice and facility design. In 2001, Introgen was awarded the manufacturing project to produce the adenoviral reference material used by companies and academic institutions developing adenovirus-based products. The awards were granted to Introgen from the Adenoviral Reference Material Working Group of Wilbio, who acted as the facilitator. The Office of Cellular and Gene Therapies of the Federal Food and Drug Administration (FDA) advised on the award grants.
Details on the two presentations are:
Shuyuan Zhang, Ph.D., Introgen’s director of Analytical Sciences and Process Development, will speak on “Engineering Solutions to the Manufacture of Adenoviral-Based Pharmaceuticals” - Wednesday, November 16, 2:15 pm
David L. Parker, Ph.D, J.D. Introgen’s vice president for Intellectual Property, will be talking on “Guidelines for Protecting Intellectual Property: An In-Company Prospective” - Wednesday, November 16, 5:00 pm
Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using tumor suppressors, cytokines and genes. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.
Statements in this release that are not strictly historical may be “forward-looking” statements, including those relating to Introgen’s future success with its clinical development program for treatment of cancer or other diseases, the manufacture of its adenoviral based pharmaceuticals and the development of its intellectual property. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgen’s operations and business environment, including Introgen’s stage of product development and the limited experience in the development of gene- based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen’s product candidates, the ability to obtain the appropriate regulatory approvals, Introgen’s patent protection and market acceptance, as well as other risks detailed from time to time in Introgen’s filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.
Editor’s Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen’s Website at: http://www.introgen.com .
Contact: Introgen Therapeutics, Inc. C. Channing Burke (512) 708 9310 Ext. 322 Email: c.burke@introgen.com
Introgen Therapeutics, Inc.
CONTACT: C. Channing Burke of Introgen Therapeutics, Inc.,+1-512-708-9310, ext. 322, or c.burke@introgen.com
Web site: http://www.introgen.com/
